Bone mineral hydroxyapatite and metallic implant surfaces

The bone mineral phase is primarily composed of hydroxyapatite [Ca10(PO4)6(OH)2], a crystalline form of calcium phosphate that provides structural rigidity to the skeletal system and acts as a reservoir for essential ions (Glimcher, 2006, PMID: 17032541). Metallic implant surfaces, typically fabricated from titanium or cobalt-chromium alloys, are engineered to facilitate osseointegration, which is the direct structural and functional connection between living bone and the surface of an artificial implant (Brånemark, 1983, PMID: 6399798). While not a traditional molecular target such as a protein or receptor, the bone mineral phase is the pharmacological site of action for bone-seeking drugs like bisphosphonates, which bind to hydroxyapatite to inhibit osteoclast activity and reduce bone resorption (Russell, 2008, PMID: 18180032). Metallic surfaces are often modified with bioactive coatings or textures to enhance this interaction and improve the long-term stability of orthopedic and dental prostheses. This interface is critical in the management of metabolic bone diseases and the success of reconstructive surgeries. Challenges at this interface include aseptic loosening, metal ion hypersensitivity, and periprosthetic infections, which remain significant hurdles in clinical orthopedics.

Other names

HydroxyapatiteBone mineral phaseImplant-bone interfaceMetallic biomaterialsHApTitanium implant surface

Bisphosphonates and bone-seeking radiopharmaceuticals bind to the hydroxyapatite mineral phase via high-affinity chelation of calcium ions; metallic implants achieve stability through osseointegration, involving protein adsorption and osteoblast adhesion to the metal oxide surface layer.